Nureca Limited

BSE: 543264 NSE: NURECA
Nureca Limited - healthcare in Mumbai, Maharashtra, India. FY 2026 financials & compliance.
CIN L24304MH2016PLC320868 Incorporated 02 November 2016 ROC Mumbai HQ Mumbai, Maharashtra, India
Active Listed - NSE: NURECA · BSE: 543264 Public Limited Company healthcare MSME · Medium
Data last updated
Market Cap
₹318 Cr
NURECA · NSE
Share Price
₹316.70
-4.99% today
Revenue
₹147 Cr
FY 2025-26 · +34.0% YoY
EBITDA
₹0.16 Cr
Margin 0.1%
Net Profit
₹2.08 Cr
FY 2025-26 · +170.1% YoY
P/E (TTM)
65.9x
P/B 1.7x
ROE
1.1%
ROCE 3.3%
Debt / Equity
0.02
Interest cover -68.8x

About Nureca Limited

Data last updated:

Nureca Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the medical and laboratory equipment segment of the healthcare sector. It was incorporated on 02 November 2016 and has been in existence for over 10 years.

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L24304MH2016PLC320868. Its GSTIN is 27AAFCN4006M1ZD (Maharashtra). The company holds 8 GST registrations, all of them active. It is a listed company as per MCA records. Its shares are listed on BSE: 543264 and NSE: NURECA.

The company has an authorised share capital of ₹11 Cr and a paid-up capital of ₹9.54 Cr. It was formerly known as Nureca Private Limited. It is led by directors including Saurabh Goyal (Managing Director) and Smita Goyal (Whole-Time Director).

Its last annual general meeting (AGM) was held on 28 July 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mumbai, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹146.96 Cr, a growth of 34% compared to the previous year. For the same year it recorded a net profit of ₹2.08 Cr (net margin 1.4%) and EBITDA of ₹16 Lakh (EBITDA margin 0.1%). The net worth stands at ₹180.76 Cr (down 7% YoY). Total assets are valued at ₹183.81 Cr (down 8.1% YoY).

The company has about 117 employees on its provident fund (EPFO) records. Its group structure includes 2 subsidiaries.

The company is associated with 1 brand: Nureca. As per MCA filings, the company has open charges of ₹72.68 Cr and satisfied charges of ₹44.12 Lakh on record. Court records list 19 cases involving the company, including 14 filed by the company and 5 filed against it; 5 cases are pending. The company has 44 deals on record (40 market trades, 2 funding rounds, 1 secondary share transfer), with disclosed funding of ₹11 Cr; the latest was in October 2025. Its 3 peer companies in the Healthcare industry (Healthcare Products, Medical and Laboratory Equipment), with the same principal business activity (wholesale trading) are compared by revenue, 1 larger and 2 smaller; the largest is Spectris Technologies Private Limited with revenue of ₹125.55 Cr. The company has 2 MSME Form 1 returns on record for the period ending Sep 2021, listing 76 overdue payments to 6 micro and small suppliers.

Nureca Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-MH-19-0049251). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website nureca.com.

Company details

CIN L24304MH2016PLC320868
Registration Number 320868
Incorporation Date 02 November 2016
ROC Mumbai
Listing Status Listed - Listed on NSE (NURECA); Listed on BSE (543264)
Company Status Active
Date of Last AGM 28 July 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-MH-19-0049251

CIN history

Nureca has 3 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24304MH2016PLC320868, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24304MH2016PLC320868Current
U24304DL2016PTC307786Previous
U24304MH2016PLC320868Previous
U24304MH2016PTC320868Previous
Key People
Saurabh Goyal Managing Director Smita Goyal Whole-Time Director Rajinder Sharma Whole-Time Director

Recognitions & Rankings of Nureca

MSME (Udyam registered) Ministry of MSME
Category
Medium (2024-25)
Udyam number
UDYAM-MH-19-0049251

Contact details

Nureca Limited's registered office is in Mumbai, Maharashtra. Its website is nureca.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    nureca.com
  • Social Media
  • Apps
  • Registered Address
    Andheri West B – 205 Bldg – 42 B Wing Dhanashree Heights, Azad Nagar Sangam Chs Andheri West, Mumbai, Maharashtra, India – 400053
  • Industry
    Healthcare, Medical & Laboratory Equipment

To see the full contact details of Nureca Limited, buy the company report.

Comprehensive company report
Nureca Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Nureca operates one associated brand: Nureca. Each brand links to its own profile.

BrandDescriptionWebsite
Nureca
Health and wellness devices are manufactured by Nureca in India.nureca.com

Business activity

The main business activity of Nureca is trade. In detail, this covers wholesale trading.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
GTradeG1Wholesale Trading

To see the full business activity and turnover split of Nureca Limited, buy the company report.

Financials of Nureca Limited

FY 2025-26 filings available

Nureca Limited reported revenue of ₹146.96 Cr (up 34% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹147 Cr
+34.0% YoY
EBITDA
₹0.16 Cr
+102.1% YoY
Profit After Tax
₹2.08 Cr
+170.1% YoY
Net Worth
₹181 Cr
-7.0% YoY
Total Assets
₹184 Cr
-8.1% YoY
Total Debt
₹2.26 Cr
-54.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue14711091.9311125621399.43
Revenue growth+34.0%+19.3%-17.4%-56.4%+19.7%+114.7%-
EBITDA0.16(7.54)(10.21)(15.02)55.5161.539.68
EBITDA margin+0.1%-6.9%-11.1%-13.5%+21.7%+28.8%+9.7%
Profit before tax4.961.35(2.55)(10.75)60.9962.338.60
Net profit2.080.77(6.11)(10.70)44.4946.376.38
Net profit margin+1.4%+0.7%-6.7%-9.6%+17.4%+21.7%+6.4%
EPS (₹)2.180.85(1.79)(8.25)44.9646.376,395.00
Balance sheet
Total assets18420019719920816724.81
Net worth18119419319520316314.93
Total debt2.264.972.523.334.413.899.78
Cash & bank41.4212745.3070.9784.351270.07
Net working capital10117990.4012016216323.68
Cash flow
Cash from operations3.30(19.08)(2.71)10.231.4034.87(7.92)
Cash from investing14.498.4317.57(16.47)(3.09)(110)(0.39)
Cash from financing(19.56)(0.17)(1.30)(1.51)(7.30)92.348.28
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue58.5340.3435.4139.6437.7434.1831.7426.46
Revenue growth (YoY)+55.1%+18.0%+11.6%+49.8%+21.0%+68.6%--
Other income1.351.821.022.192.322.571.991.48
EBITDA5.233.42(5.78)3.253.27(0.56)1.20(4.02)
EBITDA margin+8.9%+8.5%-16.3%+8.2%+8.7%-1.6%+3.8%-15.2%
Depreciation0.810.610.450.500.540.530.520.54
Interest0.260.200.300.280.460.250.620.18
Profit before tax5.514.43(5.51)4.664.591.232.05(3.26)
Tax1.461.370.590.930.970.42(0.41)(0.45)
Net profit4.053.06(6.10)3.733.620.812.46(2.81)
EPS (₹)4.253.21(6.45)3.913.630.812.47(2.80)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue14711510311727022599.43
Revenue growth+28.4%+11.8%-12.5%-56.6%+20.2%+126.1%-
EBITDA(2.61)(9.74)(11.14)(15.39)55.7861.689.70
EBITDA margin-1.8%-8.5%-10.9%-13.1%+20.7%+27.4%+9.8%
Profit before tax2.83(0.47)(3.28)(10.95)61.3462.498.62
Net profit0.29(0.77)(2.45)(8.16)44.8446.536.40
Net profit margin+0.2%-0.7%-2.4%-7.0%+16.6%+20.7%+6.4%
EPS (₹)0.31(0.67)(2.44)(8.42)45.3146.536,410.00
Balance sheet
Total assets18019719619920816824.78
Net worth17719219319520416314.97
Total debt2.214.112.433.254.333.819.70
Cash & bank41.3512745.2070.8684.191260.04
Net working capital96.0417487.3711816116223.61
Cash flow
Cash from operations0.32(18.82)(3.00)12.051.8335.10(7.85)
Cash from investing16.508.8317.84(18.30)(3.37)(110)(0.39)
Cash from financing(18.61)(0.79)(1.28)(1.51)(7.30)92.348.20
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue58.6040.4035.4139.6437.8434.3231.7527.21
Revenue growth (YoY)+54.9%+17.7%+11.5%+45.7%+16.9%+47.2%--
Other income1.421.921.062.292.382.592.001.52
Total expenses54.0537.9541.9537.2535.2235.4031.1831.94
EBITDA4.552.45(6.54)2.392.62(1.08)0.57(4.73)
EBITDA margin+7.8%+6.1%-18.5%+6.0%+6.9%-3.1%+1.8%-17.4%
Depreciation0.760.570.430.460.480.480.480.49
Interest0.220.180.240.180.410.200.590.14
Profit before tax4.993.62(6.15)4.044.110.831.50(3.84)
Tax1.371.190.480.820.970.28(0.58)(0.56)

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 23 Oct 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue58.5340.3435.4139.6437.7434.1831.7426.46
Revenue growth (YoY)+55.1%+18.0%+11.6%+49.8%+21.0%+68.6%--
Other income1.351.821.022.192.322.571.991.48
EBITDA5.233.42(5.78)3.253.27(0.56)1.20(4.02)
EBITDA margin+8.9%+8.5%-16.3%+8.2%+8.7%-1.6%+3.8%-15.2%
Depreciation0.810.610.450.500.540.530.520.54
Interest0.260.200.300.280.460.250.620.18
Profit before tax5.514.43(5.51)4.664.591.232.05(3.26)
Tax1.461.370.590.930.970.42(0.41)(0.45)
Net profit4.053.06(6.10)3.733.620.812.46(2.81)
EPS (₹)4.253.21(6.45)3.913.630.812.47(2.80)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue14711091.9311125621399.43
Revenue growth+34.0%+19.3%-17.4%-56.4%+19.7%+114.7%-
Other income8.1012.4410.517.117.702.820.06
Total expenses14711710212620015289.75
Employee cost17.0415.3112.2016.069.914.583.16
EBITDA0.16(7.54)(10.21)(15.02)55.5161.539.68
EBITDA margin+0.1%-6.9%-11.1%-13.5%+21.7%+28.8%+9.7%
Depreciation2.022.342.362.391.480.420.37
Interest1.281.210.490.450.741.600.77
Profit before tax4.961.35(2.55)(10.75)60.9962.338.60
Tax2.900.49(0.75)(2.49)16.0215.962.22
Net profit2.080.77(6.11)(10.70)44.4946.376.38
Net profit margin+1.4%+0.7%-6.7%-9.6%+17.4%+21.7%+6.4%
EPS (₹)2.180.85(1.79)(8.25)44.9646.376,395.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital9.5410.0010.0010.0010.0010.000.01
Reserves & surplus17118418318519315314.92
Shareholders' funds (net worth)18119419319520316314.93
Minority interest0.000.000.000.000.000.000.00
Secured loans0.692.250.400.000.000.000.00
Unsecured loans1.572.722.123.334.413.899.78
Total debt2.264.972.523.334.413.899.78
Total liabilities18420019719920816724.81
Assets
Gross block19.7714.3210.1910.5911.874.491.46
Net block13.589.007.118.6510.183.681.06
Capital work in progress0.000.000.270.000.420.300.00
Investments1.011.0493.6359.0933.190.000.00
Inventories47.5139.9230.8534.4863.1836.7816.43
Sundry debtors7.753.321.624.302.893.7012.90
Cash & bank balances41.4212745.3070.9784.351270.07
Loans & advances16.9918.2821.1917.7422.5813.953.35
Total current assets11418998.9612717318132.75
Total current liabilities12.3410.038.567.5911.1218.329.07
Net working capital10117990.4012016216323.68
Total assets18420019719920816724.81
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3.2414.060.508.2517.240.070.11
Net cash from operating activities3.30(19.08)(2.71)10.231.4034.87(7.92)
Net cash from investing activities14.498.4317.57(16.47)(3.09)(110)(0.39)
Net cash from financing activities(19.56)(0.17)(1.30)(1.51)(7.30)92.348.28
Net change in cash(1.78)(10.82)13.56(7.75)(8.99)17.17(0.04)
Closing cash41.4212745.3070.9784.351270.07
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+34.0%+19.3%-17.4%-56.4%+19.7%+114.7%-
EBITDA growth+102.1%+26.2%+32.0%-127.1%-9.8%+535.6%-
PBT growth+267.4%+9998.0%+76.3%--2.2%+624.8%-2.8%
Net income growth+170.1%+112.6%+42.9%-124.1%-4.1%+626.8%-
Revenue CAGR (3Y)+9.7%-24.6%-24.5%+3.8%+60.4%--
EBITDA CAGR (3Y)----+83.0%--
Profitability & leverage
Net income margin+1.4%+0.8%-2.0%-7.4%+17.6%+21.7%+6.4%
Return on capital employed+3.3%+1.3%-4.0%-6.3%+32.9%+66.9%+60.1%
Return on net worth+1.1%+0.4%-3.1%-5.4%+24.6%+52.4%+61.2%
Debt / equity0.020.020.020.020.020.080.49
Long-term debt / equity0.010.010.010.010.020.070.48
Interest cover-68.82-12.25-3.90-2.581.372.628.27
Efficiency & per share
Fixed asset turnover8.628.958.859.9131.2486.072,209.56
Inventory turnover3.363.102.812.285.118.026.63
Debtors turnover26.5544.4031.0630.9777.5625.729.14
EPS (₹)2.180.85(1.79)(8.25)44.9646.376,395.00
Dividend per share (₹)0.000.000.000.003.002.000.00
Book value per share (₹)189.44194.29193.11194.88203.20163.1013,944.00
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue58.6040.4035.4139.6437.8434.3231.7527.21
Revenue growth (YoY)+54.9%+17.7%+11.5%+45.7%+16.9%+47.2%--
Other income1.421.921.062.292.382.592.001.52
Total expenses54.0537.9541.9537.2535.2235.4031.1831.94
EBITDA4.552.45(6.54)2.392.62(1.08)0.57(4.73)
EBITDA margin+7.8%+6.1%-18.5%+6.0%+6.9%-3.1%+1.8%-17.4%
Depreciation0.760.570.430.460.480.480.480.49
Interest0.220.180.240.180.410.200.590.14
Profit before tax4.993.62(6.15)4.044.110.831.50(3.84)
Tax1.371.190.480.820.970.28(0.58)(0.56)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue14711510311727022599.43
Revenue growth+28.4%+11.8%-12.5%-56.6%+20.2%+126.1%-
Other income8.3212.5410.567.177.722.820.06
Total expenses15012411413321416389.73
Employee cost15.4314.3611.5715.519.834.583.16
EBITDA(2.61)(9.74)(11.14)(15.39)55.7861.689.70
EBITDA margin-1.8%-8.5%-10.9%-13.1%+20.7%+27.4%+9.8%
Depreciation1.852.152.242.301.430.410.37
Interest1.031.120.460.430.731.600.77
Profit before tax2.83(0.47)(3.28)(10.95)61.3462.498.62
Tax2.540.21(0.83)(2.54)16.0215.962.22
Net profit0.29(0.77)(2.45)(8.16)44.8446.536.40
Net profit margin+0.2%-0.7%-2.4%-7.0%+16.6%+20.7%+6.4%
EPS (₹)0.31(0.67)(2.44)(8.42)45.3146.536,410.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital9.5410.0010.0010.0010.0010.000.01
Reserves & surplus16818218318519415314.96
Shareholders' funds (net worth)17719219319520416314.97
Secured loans0.671.520.400.000.000.000.00
Unsecured loans1.542.592.033.254.333.819.70
Total debt2.214.112.433.254.333.819.70
Total liabilities18019719619920816824.78
Assets
Gross block17.8512.669.159.8710.484.161.44
Net block12.297.796.338.089.783.371.07
Capital work in progress0.000.000.000.000.420.300.00
Investments4.064.1096.6962.1434.490.820.05
Inventories45.4135.5528.7632.8363.1736.7816.43
Sundry debtors9.784.531.814.272.870.2312.90
Cash & bank balances41.3512745.2070.8684.191260.04
Loans & advances12.9215.9219.7416.9622.3117.303.32
Total current assets10918395.5112517318132.69
Total current liabilities13.428.918.147.4011.0518.339.08
Net working capital96.0417487.3711816116223.61
Total assets18019719619920816824.78
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3.1913.960.408.1617.000.040.08
Net cash from operating activities0.32(18.82)(3.00)12.051.8335.10(7.85)
Net cash from investing activities16.508.8317.84(18.30)(3.37)(110)(0.39)
Net cash from financing activities(18.61)(0.79)(1.28)(1.51)(7.30)92.348.20
Net change in cash(1.79)(10.77)13.56(7.76)(8.84)16.96(0.05)
Closing cash41.3512745.2070.8684.191260.04
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+28.4%+11.8%-12.5%-56.6%+20.2%+126.1%-
EBITDA growth+73.2%+12.6%+27.6%-127.6%-9.6%+535.9%-
PBT growth+9998.0%+85.7%+70.1%--1.8%+624.9%-
Net income growth+137.7%+68.6%+70.0%-118.2%-3.6%+627.0%-
Revenue CAGR (3Y)+7.9%-24.9%-23.0%+5.6%+617.9%+625.0%+1606.7%
EBITDA CAGR (3Y)-44.7%---+1017.2%+1355.6%-
Profitability & leverage
Net income margin+0.2%-0.6%-2.4%-7.2%+16.8%+20.7%+6.4%
Return on capital employed+2.1%+0.3%-1.4%-5.2%+33.0%+66.7%+75.6%
Return on net worth+0.2%-0.4%-1.3%-4.2%+24.7%+52.2%+85.4%
Debt / equity0.020.020.010.020.020.080.65
Long-term debt / equity0.010.010.010.010.020.070.62
Interest cover-23.09-9.42-3.44-2.431.342.618.25
Efficiency & per share
Fixed asset turnover9.6510.5110.7811.5136.9080.30132.57
Inventory turnover3.643.573.332.445.418.4511.51
Debtors turnover20.5736.1633.7432.82174.2834.2515.26
EPS (₹)0.31(0.67)(2.44)(8.42)45.3146.536,410.00
Dividend per share (₹)0.000.000.000.003.002.000.00
Book value per share (₹)185.66192.48192.86195.26203.74163.2914,970.00

To see the full year-wise statements and ratios of Nureca Limited, buy the company report.

Board of directors of Nureca Limited

Nureca has 8 current directors and 11 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Smita Goyal
Also directs: Mighty Humans Private Limited
Whole-Time Director01 Jun 20260 Years 4 MonthsCurrent
Saurabh Goyal
Also directs: Nectar Biopharma Private Limited, Trumom Private Limited, Nureca Technologies Private Limited and 2 more
Managing Director11 Feb 20179 Years 8 MonthsCurrent
Charu Singh
Also directs: Alphabetz Ventures Private Limited
Director21 Oct 20206 Years 0 MonthsCurrent
Ruchita Agarwal
Also directs: Aarpee Bio Private Limited
Director29 Oct 20205 Years 11 MonthsCurrent
Rajinder Sharma
Also directs: Nectar Biopharma Private Limited, Nureca Technologies Private Limited
Whole-Time Director28 May 20224 Years 4 MonthsCurrent
Vijay Kumar Sharma
Also directs: Tata Steel Limited, Reliance Power Limited, Mahindra and Mahindra Financial Services Limited and 1 more
Director21 Oct 20206 Years 0 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Peer comparison

Nureca Limited is compared with the 3 companies closest to it by revenue in the Healthcare industry (Healthcare Products, Medical and Laboratory Equipment), with the same principal business activity (wholesale trading), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Nureca Limitedthis company₹146.96 Cr (FY 2026)₹2.08 Cr1.4%34.0%117Mumbai, Maharashtra, India
Spectris Technologies Private Limited₹125.55 Cr (FY 2025)-5.0%New Delhi, Delhi, India
Orikam Healthcare India Private Limited₹122.05 Cr (FY 2025)18.0%Gurgaon, Haryana, India
GC India Dental Private Limited₹121.28 Cr (FY 2025)142.0%Sangareddy, Telangana, India

To see the full peer comparison of Nureca Limited, buy the company report.

Auditor

Nureca Limited is audited by BSR & CO. LLP for the financial year 2023.

Auditor firmFinancial yearFirm registration number
BSR & CO. LLPFY 2023101248W/W-100022

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 68.10%, foreign institutional investors hold 0.10%, domestic institutional investors hold 0.30% and retail and other public shareholders hold 31.60%.

Promoters: 68.10%DII (Domestic Institutional): 0.30%FII (Foreign Institutional): 0.10%Retail & Others: 31.60%
Sep 2026
QUARTER
68.10% Promoters
0.30% DII (Domestic Institutional)
0.10% FII (Foreign Institutional)
31.60% Retail & Others
Promoter holding - history
Now 68.10% · Sep 2026High 68.10% · Jun 2026Low 65.00% · Dec 2025
64%65.5%67%68.5%70%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 65.00%Mar 2026: 65.00%Jun 2026: 68.10%Sep 2026: 68.10%68.10%65.00%68.10%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters68.10%68.10%65.00%65.00%
Public31.90%31.90%35.00%35.00%

Charges & borrowings

Open charges
₹72.68 Cr
Satisfied charges
₹44.12 Lakh
Breakdown by lending institutions
Others₹71.39 Cr
Axis Bank Limited₹1.29 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
22 Jun 2026101333601Axis Bank Limited₹1.29 CrOpen
30 Apr 2024100922220Others₹19.99 CrOpen
26 Apr 2024100918113Others₹1 CrOpen
16 Oct 2023100812805Others₹43 LakhOpen
04 Jun 2021100448999Others₹49.97 CrOpen

To see the full charge records of Nureca Limited, buy the company report.

Total charge records: 6 View all charges

Deals & funding

Nureca Limited has 44 deals on record (40 market trades, 2 funding rounds, 1 secondary share transfer), with disclosed funding of ₹11 Cr; the latest was in October 2025.

Total deals
44
Market trades
40
Funding rounds
2
Secondary share transfer
1
IPO
1
Disclosed funding
₹11 Cr

Deals on record (5 of 44)

WhenDealAmountParties
Jan 2025Market trade₹7.31 CrBuyer: Copthall Mauritius Investment Limited, Aakraya Research LLP
Seller: Aakraya Research LLP
Jan 2025Market trade₹2.39 CrBuyer: Elixir Wealth Management Private Limited
Seller: Elixir Wealth Management Private Limited
Jan 2025Market trade₹13.45 CrBuyer: N V Investments, NK Securities Research Private Limited , Elixir Wealth Management Private Limited , an individual
Seller: NK Securities Research Private Limited , Elixir Wealth Management Private Limited , an individual
Sep 2024Market trade₹2 CrBuyer: Magpro Securities Private Limited
Seller: Magpro Securities Private Limited
Dec 2023Market trade₹14.42 CrBuyer: Graviton Research Capital LLP , Qe Securities LLP , Aakraya Research LLP
Seller: Graviton Research Capital LLP , Qe Securities LLP , Aakraya Research LLP

To see the full deal history of Nureca Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

Nureca Limited has 2 MSME Form 1 returns on record for the period ending Sep 2021, listing 76 overdue payments to 6 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 6)

SupplierAmount dueDue sinceReported on
an individual supplier
an individual supplier
an individual supplier
an individual supplier
Paradise Enterprises

To see the full MSME payment records of Nureca Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Nureca has 2 subsidiary companies. This group structure data is as of FY 2023. The table lists each entity with its relationship and holding.

2
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Nureca Technologies Private LimitedU33110PB2020PTC051368
Nureca Healthcare Private LimitedU33119PB2020PTC051608

To see the full group structure of Nureca Limited, buy the company report.

Employees & EPFO

Nureca Limited has a workforce of 117 employees on its EPFO records as of Mar 27, 2024, across 1 active EPFO establishment.

Employee count
117
Active EPFO establishments
1
Employee growth
-16.43%

GST

Nureca has 8 GST registrations: 8 active. The first 4 active GSTINs are listed below.

Total GSTINs
8
Active
8
GSTINStateStatusRegistered on
27AAFCN4006M1ZDMaharashtraActive01 Jul 2017
03AAFCN4006M1ZNPunjabActive01 Jul 2017
04AAFCN4006M1ZLChandigarhActive06 Dec 2018
36AAFCN4006M1ZETelanganaActive22 Dec 2018

To see the full GST registrations and return filing status of Nureca Limited, buy the company report.

Recent activity

Nureca Limited has 22 board changes on record since 2016: 15 appointments and 7 cessations. The latest: Smita Goyal was appointed as Whole-Time Director on 01 Jun 2026.

AGM
Nureca Limited last Annual general meeting of members was held on 28 Jul 2026 as per latest MCA records.
Charges
A charge with Axis Bank Limited amounted to Rs. 1.29 Cr with Charge ID 101333601 was registered on 22 Jun 2026.
Appointed
Smita Goyal was appointed as Whole-Time Director.
Filing
Nureca Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai I.
Charges
A charge with Others of Rs. 19.99 Cr registered on 30 Apr 2024 with Charge ID 100922220 was modified on 30 Sep 2025.
Charges
A charge registered on 19 Feb 2025 via Charge ID 101077365 with Others was fully satisfied on 16 Sep 2025.
Ceased
Vikram Chaudhery ceased to be Director.
Charges
A charge with Others amounted to Rs. 0.44 Cr with Charge ID 101077365 was registered on 19 Feb 2025.
Appointed
Kuldip Kumar Bhasin was appointed as Director.
Appointed
Rupinder Tewari was appointed as Director.
Charges
A charge with Others amounted to Rs. 19.99 Cr with Charge ID 100922220 was registered on 30 Apr 2024.
Charges
A charge with Others amounted to Rs. 1.00 Cr with Charge ID 100918113 was registered on 26 Apr 2024.

21 earlier events are in the company report.

News

Frequently asked questions

Nureca is an active public limited company based in Mumbai, Maharashtra, India. The company works in medical and laboratory equipment, within the healthcare industry. It was incorporated on 02 November 2016 (10+ years old) and is registered under CIN L24304MH2016PLC320868. Listed on BSE: 543264 and NSE: NURECA.

Nureca reported revenue of ₹146.96 Cr for FY 2025-26 (up 34% YoY) based on consolidated financials.

Nureca has 8 current directors:

The latest financial statements of Nureca on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 28 July 2026. Year-wise statements from FY 2017 are in the company report.

The GSTIN of Nureca is 27AAFCN4006M1ZD, registered in Maharashtra. The company has 8 GST registrations in all, of which 8 are active. Other active GSTINs include 03AAFCN4006M1ZN (Punjab), 04AAFCN4006M1ZL (Chandigarh), 36AAFCN4006M1ZE (Telangana).

The CIN (Corporate Identification Number) of Nureca is L24304MH2016PLC320868. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Nureca is a listed company as per MCA records. Its shares are listed on both BSE (code: 543264) and NSE (symbol: NURECA).

Nureca has 19 court cases on record: 14 filed by the company and 5 filed against it. 5 are pending. Most are in the high courts.

Nureca was incorporated on 02 November 2016, making it 10+ years old. It is registered with the Registrar of Companies, Mumbai.

Nureca has 44 deals on record (40 market trades, 2 funding rounds, 1 secondary share transfer), with disclosed funding of ₹11 Cr; the latest was in October 2025.

The peers of Nureca by revenue are Spectris Technologies Private Limited, Orikam Healthcare India Private Limited, GC India Dental Private Limited, all in the Healthcare industry (Healthcare Products, Medical and Laboratory Equipment), with the same principal business activity (wholesale trading).

Smita Goyal was appointed as Whole-Time Director on 01 Jun 2026. Vikram Chaudhery ceased to be Director on 05 May 2025. Kuldip Kumar Bhasin was appointed as Director on 01 Jan 2025. Nureca has 22 board changes on record in total.